LXRX — Lexicon Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00- $247.18m
- $109.52m
- $31.08m
- 37
- 15
- 44
- 23
Annual income statement for Lexicon Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 24 | 0.298 | 0.139 | 1.2 | 31.1 |
| Cost of Revenue | |||||
| Gross Profit | 22.1 | 0.298 | 0.139 | 1.12 | 30.5 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 70.8 | 87.4 | 101 | 173 | 228 |
| Operating Profit | -46.8 | -87.1 | -101 | -172 | -197 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -58.6 | -87.8 | -102 | -177 | -200 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -58.6 | -87.8 | -102 | -177 | -200 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -58.6 | -87.8 | -102 | -177 | -200 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -58.6 | -87.8 | -102 | -177 | -200 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.72 | -0.603 | -0.615 | -0.801 | -0.626 |